299 related articles for article (PubMed ID: 19073216)
1. A preliminary and comparative evaluation of a novel Ad5 [E1-, E2b-] recombinant-based vaccine used to induce cell mediated immune responses.
Gabitzsch ES; Xu Y; Yoshida LH; Balint J; Gayle RB; Amalfitano A; Jones FR
Immunol Lett; 2009 Jan; 122(1):44-51. PubMed ID: 19073216
[TBL] [Abstract][Full Text] [Related]
2. Induction and comparison of SIV immunity in Ad5 naïve and Ad5 immune non-human primates using an Ad5 [E1-, E2b-] based vaccine.
Gabitzsch ES; Xu Y; Balint JP; Balcaitis S; Sanders-Beer B; Jones FR
Vaccine; 2011 Oct; 29(45):8101-7. PubMed ID: 21864618
[TBL] [Abstract][Full Text] [Related]
3. Novel Adenovirus type 5 vaccine platform induces cellular immunity against HIV-1 Gag, Pol, Nef despite the presence of Ad5 immunity.
Gabitzsch ES; Xu Y; Yoshida LH; Balint J; Amalfitano A; Jones FR
Vaccine; 2009 Oct; 27(46):6394-8. PubMed ID: 19559110
[TBL] [Abstract][Full Text] [Related]
4. Anti-tumor immunotherapy despite immunity to adenovirus using a novel adenoviral vector Ad5 [E1-, E2b-]-CEA.
Gabitzsch ES; Xu Y; Balint JP; Hartman ZC; Lyerly HK; Jones FR
Cancer Immunol Immunother; 2010 Jul; 59(7):1131-5. PubMed ID: 20361185
[TBL] [Abstract][Full Text] [Related]
5. Control of SIV infection and subsequent induction of pandemic H1N1 immunity in rhesus macaques using an Ad5 [E1-, E2b-] vector platform.
Gabitzsch ES; Balint-Junior JP; Xu Y; Balcaitis S; Sanders-Beer B; Karl J; Weinhold KJ; Paessler S; Jones FR
Vaccine; 2012 Nov; 30(50):7265-70. PubMed ID: 23041546
[TBL] [Abstract][Full Text] [Related]
6. The generation and analyses of a novel combination of recombinant adenovirus vaccines targeting three tumor antigens as an immunotherapeutic.
Gabitzsch ES; Tsang KY; Palena C; David JM; Fantini M; Kwilas A; Rice AE; Latchman Y; Hodge JW; Gulley JL; Madan RA; Heery CR; Balint JP; Jones FR; Schlom J
Oncotarget; 2015 Oct; 6(31):31344-59. PubMed ID: 26374823
[TBL] [Abstract][Full Text] [Related]
7. Novel adenoviral vector induces T-cell responses despite anti-adenoviral neutralizing antibodies in colorectal cancer patients.
Morse MA; Chaudhry A; Gabitzsch ES; Hobeika AC; Osada T; Clay TM; Amalfitano A; Burnett BK; Devi GR; Hsu DS; Xu Y; Balcaitis S; Dua R; Nguyen S; Balint JP; Jones FR; Lyerly HK
Cancer Immunol Immunother; 2013 Aug; 62(8):1293-301. PubMed ID: 23624851
[TBL] [Abstract][Full Text] [Related]
8. Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity.
Barouch DH; Pau MG; Custers JH; Koudstaal W; Kostense S; Havenga MJ; Truitt DM; Sumida SM; Kishko MG; Arthur JC; Korioth-Schmitz B; Newberg MH; Gorgone DA; Lifton MA; Panicali DL; Nabel GJ; Letvin NL; Goudsmit J
J Immunol; 2004 May; 172(10):6290-7. PubMed ID: 15128818
[TBL] [Abstract][Full Text] [Related]
9. An Ad5[E1-, E2b-]-HER2/neu vector induces immune responses and inhibits HER2/neu expressing tumor progression in Ad5 immune mice.
Gabitzsch ES; Xu Y; Balcaitis S; Balint JP; Jones FR
Cancer Gene Ther; 2011 May; 18(5):326-35. PubMed ID: 21233857
[TBL] [Abstract][Full Text] [Related]
10. Optimization of vaccine responses with an E1, E2b and E3-deleted Ad5 vector circumvents pre-existing anti-vector immunity.
Osada T; Yang XY; Hartman ZC; Glass O; Hodges BL; Niedzwiecki D; Morse MA; Lyerly HK; Amalfitano A; Clay TM
Cancer Gene Ther; 2009 Sep; 16(9):673-82. PubMed ID: 19229288
[TBL] [Abstract][Full Text] [Related]
11. Decreased Vector Gene Expression from E2b Gene-Deleted Adenovirus Serotype 5 Vaccines Intensifies Proinflammatory Immune Responses.
Quiroga D; Aldhamen YA; Godbehere S; Harding L; Amalfitano A
Clin Vaccine Immunol; 2017 Jun; 24(6):. PubMed ID: 28381403
[TBL] [Abstract][Full Text] [Related]
12. Comparative Evaluation of the Vaccine Efficacies of Three Adenovirus-Based Vector Types in the Friend Retrovirus Infection Model.
Hrycak CP; Windmann S; Bayer W
J Virol; 2019 Nov; 93(21):. PubMed ID: 31375593
[TBL] [Abstract][Full Text] [Related]
13. Modification of Ad5 hexon hypervariable regions circumvents pre-existing Ad5 neutralizing antibodies and induces protective immune responses.
Bruder JT; Semenova E; Chen P; Limbach K; Patterson NB; Stefaniak ME; Konovalova S; Thomas C; Hamilton M; King CR; Richie TL; Doolan DL
PLoS One; 2012; 7(4):e33920. PubMed ID: 22496772
[TBL] [Abstract][Full Text] [Related]
14. [Anti-adenovirus neutralizing antibodies and Gag-specific cellular immune responses in Macaca fascicularis immunized with Ad5-HIVgag].
Li Y; Yang L; Yang L; Chen DY; Feng X; Yu SQ; Li ZL; Zeng Y
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2011 Dec; 25(6):413-5. PubMed ID: 22734222
[TBL] [Abstract][Full Text] [Related]
15. Immunogenicity when utilizing adenovirus serotype 4 and 5 vaccines expressing circumsporozoite protein in naïve and adenovirus (Ad5) immune mice.
Schuldt NJ; Aldhamen YA; Godbehere-Roosa S; Seregin SS; Kousa YA; Amalfitano A
Malar J; 2012 Jun; 11():209. PubMed ID: 22720732
[TBL] [Abstract][Full Text] [Related]
16. A novel adenovirus type 6 (Ad6)-based hepatitis C virus vector that overcomes preexisting anti-ad5 immunity and induces potent and broad cellular immune responses in rhesus macaques.
Capone S; Meola A; Ercole BB; Vitelli A; Pezzanera M; Ruggeri L; Davies ME; Tafi R; Santini C; Luzzago A; Fu TM; Bett A; Colloca S; Cortese R; Nicosia A; Folgori A
J Virol; 2006 Feb; 80(4):1688-99. PubMed ID: 16439526
[TBL] [Abstract][Full Text] [Related]
17. Immunization With a Novel Human Type 5 Adenovirus-Vectored Vaccine Expressing the Premembrane and Envelope Proteins of Zika Virus Provides Consistent and Sterilizing Protection in Multiple Immunocompetent and Immunocompromised Animal Models.
Guo Q; Chan JF; Poon VK; Wu S; Chan CC; Hou L; Yip CC; Ren C; Cai JP; Zhao M; Zhang AJ; Song X; Chan KH; Wang B; Kok KH; Wen Y; Yuen KY; Chen W
J Infect Dis; 2018 Jul; 218(3):365-377. PubMed ID: 29617816
[TBL] [Abstract][Full Text] [Related]
18. A rapid strategy for constructing novel simian adenovirus vectors with high viral titer and expressing highly antigenic proteins applicable for vaccine development.
Luo S; Zhang P; Ma X; Wang Q; Lu J; Liu B; Zhao W; Allain JP; Li C; Li T
Virus Res; 2019 Jul; 268():1-10. PubMed ID: 31108113
[TBL] [Abstract][Full Text] [Related]
19. Long-term humoral and cellular immunity induced by a single immunization with replication-defective adenovirus recombinant vector.
Juillard V; Villefroy P; Godfrin D; Pavirani A; Venet A; Guillet JG
Eur J Immunol; 1995 Dec; 25(12):3467-73. PubMed ID: 8566039
[TBL] [Abstract][Full Text] [Related]
20. Effect of route of delivery on heterologous protection against HCV induced by an adenovirus vector carrying HCV structural genes.
Guan J; Wen B; Deng Y; Zhang K; Chen H; Wu X; Ruan L; Tan W
Virol J; 2011 Nov; 8():506. PubMed ID: 22054309
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
